Several somatic mutations have been identified in MDS suggesting that precision medicine with targeting of actionable mutations such as IDH1/2, RAS, JAK, and FLT3 may be an attractive approach [57]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.